|
Contents
|
|
|
|
Astrocytic
Tumors
|
|
|
|
|
Chamberlain
MC, Wei-Tsao DD, Blumenthal DT, Glantz MJ.
Salvage chemotherapy with CPT-11 for recurrent temozolomide-refractory
anaplastic astrocytoma
Cancer. 2008 May 1;112(9):2038-45.
Epub 2008 Mar 24
.JPG) Abstract
|
|
Michael
L. Gruber, Deborah B Gruber
Phase
II Treatment of Recurrent Malignant Astrocytoma with Temozolomide and
Irinotecan
ASCO Proceedings, 2001
Annual Meeting, Abstract No. 2043
|
|
|
Sathornsumetee S, Cao Y, Marcello JE, Herndon JE
2nd, McLendon RE, Desjardins A, Friedman HS, Dewhirst MW, Vredenburgh JJ,
Rich JN
Tumor angiogenic and hypoxic profiles predict radiographic response and
survival in malignant astrocytoma patients treated with bevacizumab and
irinotecan
J
Clin Oncol. 2008 Jan 10;26(2):271-8
Abstract
|
|
|
Glioblastoma
|
|
|
|
|
Ali SA, McHayleh WM, Ahmad A, Sehgal R, Braffet
M, Rahman M, Bejjani G, Friedland DM.
Bevacizumab and irinotecan therapy in glioblastoma multiforme: a series
of 13 cases
J Neurosurg.
2008 Aug;109(2):268-72
Abstract
|
|
|
Fadul CE, Kingman LS, Meyer LP, Cole BF, Eskey
CJ, Rhodes CH, Roberts DW, Newton HB, Pipas JM.
A phase II study of thalidomide and irinotecan for treatment of
glioblastoma multiforme
J Neurooncol. 2008 Jul 26; [Epub ahead of print]
Abstract
|
|
|
Jaeckle KA, Ballman KV, Giannini C, Schomberg PJ, Ames MM, Reid
JM, McGovern RM,
Safgren SL, Galanis E, Uhm JH, Brown PD, Hammack JE, Arusell R, Nikcevich
DA, Morton RF, Wender DB, Buckner JC
Phase
II NCCTG trial of RT + irinotecan and adjuvant BCNU plus irinotecan for
newly diagnosed GBM.
J
Neurooncol. 2010 Aug;99(1):73-80. Epub 2010 Jan 9
Abstract |
.png)
Full Text |
.png)
Reprint |
.gif)
Related articles
|
|
K. A. Jaeckle, K. V.
Ballman, P. Schomberg, J. Uhm, B.
Schiethauer, C. Giannini, S. Felton, P.
Brown, B. C. Jan NCCTG
N997D: Pilot trial of CPT11 during RT followed by CPT11 and BCNU in newly
diagnosed glioblastoma (GBM) patients: A North Central Cancer Group (NCCTG)
study
2005
ASCO Annual Meeting. Orlando, FL. May 13-17. Abstract No. 1514.
Journal of Clinical Oncology, Vol 23, No 16S (June 1 Supplement), 2005:
1514
|
|
|
Omuro AM, Delattre JY
What is the place of bevacizumab and irinotecan in the treatment of
glioblastoma and other malignant gliomas?
Curr Opin Neurol. 2008 Dec;21(6):717-719
Abstract
|
|
|
Quinn JA, Jiang SX, Reardon DA, Desjardins A,
Vredenburgh JJ, Friedman AH, Sampson JH, McLendon RE, Herndon JE 2nd,
Friedman HS
Phase
II trial of temozolomide (TMZ) plus irinotecan (CPT-11) in adults with newly
diagnosed glioblastoma multiforme before radiotherapy
J Neurooncol.
2009 Jun 17. [Epub ahead of print]
Abstract
|
|
Yinglin
Wang, Linda M. Liau, Timothy F. Cloughesy, Paul S. Mischel
p53 status determines the cell fate of
glioblastoma cells in response to SN-38
Proceedings of the AACR, Volume 44, 2nd ed., July 2003, Abstract No. 2683
|
|
|
Recurrent
Tumors
|
 
|
|
|
A. A. Brandes, A. Tosoni, M.
Reni, F. Valduga, U. Basso, S. Lonardi, L. M. Pasetto, V. Blatt, S.
Monfardini, M. Ermani
Second line BCNU plus CPT-11
chemotherapy in recurrent glioblastoma (GBM): Phase II study of GICNO
(Italian Neuro-Oncology Group)
40th
ASCO Annual Meeting. New Orleans, LA. June 5-8, 2004. Abstract No.1516
|
|
|
Chamberlain MC
Bevacizumab Plus Irinotecan in Recurrent Glioblastoma
J Clin Oncol. 2008 Feb 20;26(6):1012-1013
Abstract |
Full Text |
Reprint
|
|
Chamberlain
MC
Salvage
chemotherapy with CPT-11 for recurrent glioblastoma multiforme
J Neurooncol 2002 Jan;56(2):183-8
|
|
|
Chowdhary S, Wong ET
Bevacizumab combined with irinotecan for recurrent glioblastoma
multiforme-improvement over available therapy?
Nat Clin Pract Neurol. 2008 Jan 22. [Epub ahead of print]
Abstract
|
|
|
Friedman HS, Prados MD, Wen PY, Mikkelsen T, Schiff D, Abrey
LE, Yung WK, Paleologos N, Nicholas MK, Jensen R, Vredenburgh J, Huang J,
Zheng M, Cloughesy T
Bevacizumab Alone and in Combination With Irinotecan in Recurrent
Glioblastoma
J
Clin Oncol. 2009 Aug 31. [Epub ahead of print]
Abstract
|
|
|
Hasselbalch
B, Eriksen JG, Broholm H, Christensen IJ, Grunnet K, Horsman MR, Poulsen HS,
Stockhausen MT, Lassen U.
Prospective evaluation of angiogenic, hypoxic and EGFR-related biomarkers in
recurrent glioblastoma multiforme treated with cetuximab, bevacizumab and
irinotecan
APMIS. 2010 Aug;118(8):585-94. Published Online: 1 Jun 2010
Abstract
|
|
|
Jakobsen JN, Hasselbalch B, Stockhausen MT, Lassen U, Poulsen HS.
Irinotecan and bevacizumab in recurrent glioblastoma multiforme.
Expert Opin Pharmacother. 2011 Apr;12(5):825-33.
Abstract |
Related articles
|
|
|
Kreisl
TN, Kim L, Moore K, Duic P, Royce C, Stroud I, Garren N, Mackey M, Butman
JA, Camphausen K, Park J, Albert PS, Fine HA
Phase II Trial of Single-Agent Bevacizumab Followed by Bevacizumab Plus
Irinotecan at Tumor Progression in Recurrent Glioblastoma
J Clin Oncol. 2008 Dec 29; [Epub ahead of print]
Abstract
|
|
|
Puduvalli VK, Giglio P, Groves MD, Hess KR,
Gilbert MR, Mahankali S, Jackson EF, Levin VA, Conrad CA, Hsu SH, Colman H,
de Groot JF, Ritterhouse MG, Ictech SE, Yung WK
Phase II trial of irinotecan and thalidomide in adults with recurrent
glioblastoma multiforme
Neuro Oncol. 2008 Feb 26; [Epub ahead of print]
Abstract
|
|
|
Reardon
DA, Desjardins A, Peters KB, Gururangan S, Sampson JH, McLendon RE, Herndon
JE 2nd, Bulusu A, Threatt S, Friedman AH, Vredenburgh JJ, Friedman HS.
Phase II study of
carboplatin, irinotecan, and bevacizumab for bevacizumab
naοve,
recurrent glioblastoma.
J Neurooncol. 2011 Oct
11;. [Epub ahead of print]
Abstract |
Related articles
|
|
|
J.J. Vredenburgh,
Annick Desjardins, David A. Reardon, Henry
S. Friedman
In Reply
Journal of Clinical Oncology, Vol 26, No 6 (February 20),
2008: pp. 1013. DOI:
10.1200/JCO.2007.15.1746
Abstract |
Full Text |
Reprint
|
|
|
Vredenburgh JJ, Desjardins A, Herndon JE 2nd, Marcello J, Reardon DA, Quinn JA, Rich
JN,
Sathornsumetee S, Gururangan S, Sampson J, Wagner M, Bailey L, Bigner DD,
Friedman AH, Friedman HS.
Bevacizumab plus irinotecan in recurrent glioblastoma multiforme
J
Clin Oncol. 2007 Oct 20;25(30):4722-9.
Abstract |
Full
Text |
Reprint
|
|
|
Gliomas
|
|
|
|
Mary
L Affronti, David Reardon, Deborah Allen, Rodney Beason, Sridharan
Gururangan, Allan Friedman, James Herndon, Susanne Jackson, Roger McLendon,
Jennifer Quinn, Jeremy Rich, John Sampson, Amy Walker, Darell D Bigner, Henry
Friedman
A
phase II study of CPT-11 plus BCNU for adults with high grade glioma
38th
ASCO Annual Meeting. Orlando, FL. May 18-21, 2002.
Abstract No. 2091
|
|
Friedman HS, Keir S, Pegg AE, Houghton PJ, Colvin OM, Moschel RC,
Bigner DD, Dolan ME
O6-benzylguanine-mediated
enhancement of chemotherapy
Mol Cancer Ther 2002
Sep;1(11):943-8
|
|
Allan
H Friedman, Sunil Agarwal, Brandon Evans, Amy Walker, Sandra
Tourt-Uhlig, David Reardon, Mary L Affronti, Deborah Allen, Rodney Beason,
Sridharan Gururangan, Susanne Jackson, Roger McLendon, Jennifer Quinn,
Jeremy Rich, John Sampson, Valerie Stafford-Fox, Karen Ziegler, Darell D
Bigner, Henry Friedman
Novel use of Gliadel for gliomas
38th ASCO Annual Meeting. Orlando, FL. May 18-21, 2002. 2109
|
|
|
Kuroda JI, Kuratsu JI, Yasunaga M, Koga Y, Saito Y, Matsumura
Y
Potent antitumor effect of SN-38-incorporating polymeric micelle, NK012,
against malignant glioma
Int J Cancer. 2008 Nov 24;. [Epub ahead of print]
Abstract |
Full Text |
Reprint
|
|
Patel
VJ, Elion GB, Houghton PJ, Keir S, Pegg AE, Johnson SP, Dolan ME,
Bigner DD, Friedman HS
Schedule-dependent
activity of temozolomide plus CPT-11 against a human central nervous
system tumor-derived xenograft
Clin Cancer Res 2000
Oct;6(10):4154-7 (PDF Full Text)
|
|
D.A. Reardon, Jennifer A.
Quinn, Jeremy N. Rich, Sridharan Gururangan, James Vredenburgh, John H. Sampson, James M. Provenzale, Amy
Walker, Michael Badruddoja, Sandra Tourt-Uhlig, James E. Herndon II, Jeannette M.
Dowell, Mary
Lou Affronti, Susanne Jackson, Deborah Allen, Karen Ziegler, Steven Silverman,
Cindy Bohlin, Allan H. Friedman, Darell D. Bigner, Henry S. Friedman
Phase 2 trial of BCNU plus irinotecan
in adults with malignant glioma
Neuro-Oncology, April 2004, Volume 6, Number 2, Pages 134 144. (Abstract+)
|
|
R.
Stupp, S. Ostermann, A. Calderoni, C. Uhlmann, S. Leyvraz
Temozolomide (TMZ) and
irinotecan (CPT-11) for primary brain tumors. A dose escalation study
39th ASCO Annual Meeting.
Chicago, IL. May 31-June 3, 2003. Abstract No.
415
|
|
|
Vredenburgh JJ, Desjardins A, Reardon DA,
Friedman HS.
Experience with irinotecan for the treatment of malignant glioma
Neuro Oncol. 2008 Sep 10; [Epub ahead of print]
Abstract
|
|
|
J. J. Vredenburgh, A. Desjardins, J. E. Herndon, J. Quinn, J. Rich, S.
Sathornsumetee, H. S. Friedman, D. Reardon, S. Gururangan, A. Friedman
Bevacizumab, a monoclonal antibody to vascular endothelial growth factor
(VEGF),
and irinotecan for treatment of malignant gliomas
Journal of Clinical Oncology, 2006 ASCO Annual Meeting Proceedings
(Post-Meeting Edition).
Vol 24, No 18S (June 20 Supplement), 2006: 1506
|
|
|
Recurrent
Tumors
|
|
|
|
W.
Adler, F. C. Lee
A
phase I trial using combination irinotecan and thalidomide for recurrent CNS
tumors
39th
ASCO Annual Meeting. Chicago, IL. May 31-June 3, 2003.
Abstract No. 489
|
|
M.
A. Badruddoja, D. Reardon, R. Beason, A. Friedman, J. A. Quinn, J.
Rich, J. Sampson, V. Stafford-Fox, D. D. Bigner, H. S. Friedman
Phase
1 study of temozolomide plus irinotecan (CPT-11) in adults with recurrent
malignant glioma
39th
ASCO Annual Meeting. Chicago, IL. May 31-June 3, 2003. Abstract No.
409
|
|
Tracy T. Batchelor, Mark R. Gilbert, Jeffrey G. Supko, Kathryn A. Carson,
Louis B. Nabors, Stuart A. Grossman, Glenn J. Lesser, Tom Mikkelsen, and Surasak
Phuphanich
Phase 2 study of weekly irinotecan in adults with recurrent malignant glioma:
Final report of NABTT 97-11
Neuro-Oncology,
January 2004, Volume 6 Number 1, Pages 21 -- 27 (Abstract+)
|
|
|
Bokstein F, Shpigel S, Blumenthal DT
Treatment with bevacizumab and irinotecan for recurrent high-grade glial
tumors
Cancer. 2008 May 15;112(10):2267-73
Abstract
|
|
J
Buckner, J Reid, L Schaaf, S Cha, K Wright, R Marks, M Wiesenfeld, A
Hatfield, J Krook, S Nair, P Schaefer, L Miller
A Phase II Trial of Irinotecan (CPT-11) in
Recurrent Glioma
ASCO Proceedings, 2000 Annual Meeting, Abstract No.
679A
|
|
|
Desjardins A, Reardon DA, Herndon JE 2nd,
Marcello J, Quinn JA, Rich JN, Sathornsumetee S, Gururangan S, Sampson J,
Bailey L, Bigner DD, Friedman AH, Friedman HS, Vredenburgh JJ.
Bevacizumab Plus Irinotecan in Recurrent WHO Grade 3 Malignant Gliomas
Clin
Cancer Res. 2008 Nov 1;14(21):7068-73
Abstract
|
|
L.G. Feun, Angela Marini,
Howard Landy, Arnold Markoe, Deborah Heros, Carlos Robles,
Cristina Herrera and Niramol Savaraj
Clinical trial of CPT-11 and VM-26/VP-16 for patients with recurrent
malignant brain tumors
J Neurooncol. 2006 Oct 19;
[Epub ahead of print]
Abstract
|
|
Friedman
HS, Petros WP, Friedman AH, Schaaf LJ, Kerby T, Lawyer J, Parry M,
Houghton PJ, Lovell S, Rasheed K, Cloughsey T, Stewart ES, Colvin OM, Provenzale
JM, McLendon RE, Bigner DD, Cokgor I, Haglund M, Rich J, Ashley D, Malczyn J,
Elfring GL, Miller LL
Irinotecan
therapy in adults with recurrent or progressive malignant glioma
J Clin Oncol 1999
May;17(5):1516-25
|
|
|
Giglio
P, Dhamne M, Hess KR, Gilbert MR, Groves MD, Levin VA, Kang SL, Ictech SE,
Liu V, Colman H, Conrad CA, Loghin M, de Groot J, Yung WK, Puduvalli VK.
Phase 2 trial of irinotecan and thalidomide in adults with recurrent
anaplastic glioma.
Cancer. 2011 Nov 15;. [Epub ahead of print]
Abstract |
Related articles
|
|
M.
R. Gilbert, P. Wen, F. Lieberman, I. Robins, M. Mehta, W. K. A. Yung, S.
Chang, L. Junck, T. Cloughesy, M. Prados
Phase I/II study of
combination temozolomide (TMZ) and irinotecan (CPT-11) for recurrent
malignant gliomas: A North American Brain Tumor Consortium (NABTC) study
39th ASCO Annual Meeting.
Chicago, IL. May 31-June 3, 2003. Abstract No.
410
|
|
|
Gururangan
S, Chi SN, Young Poussaint T, Onar-Thomas A, Gilbertson RJ, Vajapeyam S,
Friedman HS, Packer RJ, Rood BN, Boyett JM, Kun LE
Lack of Efficacy of Bevacizumab Plus Irinotecan in Children With
Recurrent Malignant Glioma and Diffuse Brainstem Glioma: A Pediatric Brain
Tumor Consortium Study
J Clin Oncol. 2010 May 17;. [Epub ahead of print]
Abstract
|
|
R. V. Larocca, A. Cervera, J.
B. Hargis, S. D. Glisson, G. H. Goldsmith, M. A. M. Laureano, B. Foreman
High-dose (HD) irinotecan in patients with
recurrent unresectable high-grade gliomas on glucoronidation-enhancing
anticonvulsants (GEACs): A phase I/II study
40th
ASCO Annual Meeting. New Orleans, LA. June 5-8, 2004. Abstract No.1578
|
|
|
Loghin ME, Prados MD, Wen P, Junck L, Lieberman
F, Fine H, Fink KL, Metha M, Kuhn J, Lamborn K, Chang SM, Cloughesy T,
Deangelis LM, Robins IH, Aldape KD, Yung WK
Phase I Study of Temozolomide and Irinotecan for Recurrent Malignant
Gliomas in Patients Receiving Enzyme-Inducing Antiepileptic Drugs: A North
American Brain Tumor Consortium Study
Clin
Cancer Res. 2007 Dec 1;13(23):7133-8
Abstract
|
|
Parker RJ, Fruehauf JP, Mehta R, Filka E, Cloughesy T
A prospective blinded study of the
predictive value of an extreme drug resistance assay in patients receiving
CPT-11 for recurrent glioma
J Neurooncol. 2004 Feb;66(3):365-75. (Abstract+)
|
|
Prados MD, Yung WK, Jaeckle KA, Robins HI, Mehta MP, Fine HA, Wen PY,
Cloughesy TF, Chang SM, Nicholas MK, Schiff D, Greenberg HS, Junck L, Fink KL,
Hess KR, Kuhn J; North American Brain Tumor Consortium study
Phase 1 trial of irinotecan (CPT-11) in patients with
recurrent malignant glioma: a North American Brain Tumor Consortium study
Neuro-oncol. 2004 Jan;6(1):44-54. (Abstract+)
|
|
|
Quinn
JA, Jiang SX, Reardon DA, Desjardins A, Vredenburgh JJ, Gururangan S,
Sampson JH, McLendon RE, Herndon JE 2nd, Friedman HS
Phase
1 trial of temozolomide plus irinotecan plus O(6)-benzylguanine in adults
with recurrent malignant glioma
Cancer. 2009 Apr 28. [Epub
ahead of print]
Abstract
|
|
Jennifer
A. Quinn, David A. Reardon, Allan H. Friedman, Jeremy N. Rich, John H.
Sampson, James Vredenburgh, Sridharan Gururangan, James M. Provenzale, Amy
Walker, Holly Schweitzer, Darell D. Bigner, Sandra Tourt-Uhlig, James E. Herndon
II, Mary Lou Affronti, Susanne Jackson, Deborah Allen, Karen Ziegler, Cindy
Bohlin, Christy Lentz, Henry S. Friedman
Phase 1 trial of irinotecan plus BCNU in
patients with progressive or recurrent malignant glioma
Neuro-Oncology, Volume 6, Number 2, Pages 145 153. (Abstract+)
|
|
|
Reardon DA, Quinn JA, Vredenburgh J, Rich JN, Gururangan S, Badruddoja M,
Herndon JE 2nd, Dowell JM, Friedman AH, Friedman HS.
Phase
II trial of irinotecan plus celecoxib in adults with recurrent
malignant glioma.
Cancer. 2005 Jan 15;103(2):329-38.
Abstract |
Reprint |
Related articles
|
|
Sandra
Tourt-Uhlig, David Reardon, Mary L Affronti, Deborah Allen, Rodney
Beason, Brandon Evans, Sridharan Gururangan, Allan Friedman, Susanne
Jackson, Roger McLendon, Jennifer Quinn, Jeremy Rich, John Sampson,
Valerie Stafford-Fox, Karen Ziegler, Darell D Bigner, Henry Friedman
Treatment of adults with recurrent
malignant glioma using temozolomide plus CPT-11: a phase I study
38th
ASCO Annual Meeting. Orlando, FL. May 18-21, 2002. 2096
|
|
|
Torcuator R, Zuniga R, Loutfi R, Mikkelsen T
Bevacizumab
and irinotecan treatment for progressive diffuse brainstem glioma: case
report
J Neurooncol.
2009 Jan 13. [Epub ahead of print]
Abstract
|
|
|
Xu
T, Chen J, Lu Y, Wolff JE.
Effects of bevacizumab plus irinotecan on response and survival in
patients with recurrent malignant glioma: a systematic review and
survival-gain analysis
BMC Cancer. 2010 Jun 2;10(1):252. [Epub ahead of print]
Abstract |
Full Text |
Reprint
|
|
|
Zuniga RM, Torcuator R, Jain R, Anderson J,
Doyle T, Ellika S, Schultz L, Mikkelsen T
Efficacy, safety and patterns of response and recurrence in patients with
recurrent high-grade gliomas treated with bevacizumab plus irinotecan
J Neurooncol.
2008 Oct 25. [Epub ahead of print]
Abstract
|
|
|
Non-CNS Tumors
|
|
|
|
Mori
K, Kondo T, Kamiyama Y, Kano Y, Tominaga K
Preventive
effect of Kampo medicine (Hangeshashin-to) against irinotecan-induced diarrhea
in advanced non-small-cell lung cancer
Cancer Chemother Pharmacol 2003 Apr 9; [epub ahead of print]
|
|
|
Oligodendroglioma
|
|
|
|
|
Chamberlain MC, Glantz MJ
CPT-11
for recurrent temozolomide-refractory 1p19q co-deleted anaplastic
oligodendroglioma
J Neurooncol.
2008 Sep;89(2):231-8. Epub 2008 May 15
Abstract
|
|
|
Taillibert S, Vincent LA, Granger B, Marie Y,
Carpentier C, Guillevin R, Bellanger A, Mokhtari K, Rousseau A, Psimaras D,
Dehais C, Sierra del Rio M, Meng Y, Laigle-Donadey F, Hoang-Xuan K, Sanson
M, Delattre JY
Bevacizumab
and irinotecan for recurrent oligodendroglial tumors
Neurology. 2009 May
5;72(18):1601-6
Abstract
|
|
|
Pediatric
Patients |
|
|
|
|
Narayana A, Kunnakkat S, Chacko-Mathew J, Gardner S,
Karajannis M, Raza S, Wisoff J, Weiner H, Harter D, Allen J.
Bevacizumab in recurrent high-grade pediatric gliomas
Neuro Oncol. 2010 Apr 2;. [Epub ahead of print
Abstract
|
|
|
Bomgaars LR, Bernstein M, Krailo M, Kadota R, Das S, Chen Z, Adamson PC, Blaney SM.
Phase II trial of irinotecan in
children with refractory solid tumors: a Children's Oncology Group Study.
J
Clin Oncol. 2007 Oct 10;25(29):4622-7.
Abstract
|
|
|
Topoisomerase
I inhibitors
|
|
|
|
Ewesuedo
RB, Ratain MJ
Topoisomerase
I Inhibitors
Oncologist 1997;2(6):359-364 (PDF Full Text)
|
|
